Pharma Exclusives Pressreleases
BioMed X Launches Women’s Health R&D Accelerator in Heidelberg
Tuesday, October 14, 2025BioMed X today announced the launch of XFem Labs a new Womens Health RD Accelerator in Heidelberg The purpose of this initiative which is supported by the Gates Foundation is to establish a worldclass womens
Lundbeck’s bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies
Monday, October 13, 2025Lundbeck today announced that its investigational drug bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies DEEs has been granted Breakthrough Therapy Designation BTD by Chinas Center for Drug Evaluat...
WHO Foundation and Lilly Collaborate to Support Global Dementia Action Plan
Monday, October 13, 2025The WHO Foundation and Lilly have announced a collaboration to financially support the aims of the World Health Organizations global action plan on the public health response to dementia
Roche receives CE Mark for AI-based Kidney Klinrisk Algorithm(1) and launches new comprehensive chronic kidney disease (CKD) algorithm panel
Monday, October 06, 2025Rochein collaboration with KlinRisk Inc has received the CEmark for the first AIbased risk stratification tool to assess progressive decline in kidney function This milestone allows Roche to introduce the Chronic Kidney Disease CKD
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
Friday, September 26, 2025CSL Vifor and Travere Therapeutics Inc support the recent publication of the updated clinical practice guidelines for the treatment of IgA Nephropathy IgAN Kidney Disease Improving Global Outcomes KDIGO clinical practice guideline for the management...
Tezspire recommended for approval in the EU by CHMP for chronic rhinosinusitis with nasal polyps
Monday, September 22, 2025AstraZeneca and Amgens Tezspire tezepelumab has been recommended for approval in the European Union EU for the treatment of adult patients with chronic rhinosinusitis with nasal polyps CRSwNP
ToxTracker® Approved by OECD for Incorporation into Test Guideline Programme
Thursday, September 04, 2025Toxys a leading innovator in animalfree toxicology solutions announces that its flagship product ToxTracker has been accepted into the Organization for Economic Cooperation and Development OECD
CrystalsFirst to Exclusively Offer NexMRʼs Ultrafast NMR Screening Technology for Fragment-Based Drug Discovery
Thursday, September 04, 2025CrystalsFirst GmbH a leader in highperformance structural biology services and NexMR AG a pioneer in ultrafast NMR screening today announced an exclusive partnership to accelerate fragmentbased drug discovery
Quotient Sciences and CPI to Accelerate RNA Drug Development with Joint Venture
Wednesday, September 03, 2025Quotient Sciences a leading global drug development and manufacturing accelerator and UK technology innovation centre CPI have signed a memorandum of understanding MoU to form a Joint Venture
Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
Monday, September 01, 2025Boehringer Ingelheims HERNEXEOS zongertinib tablets has been approved as monotherapy by Chinas National Medical Products Administration NMPA for the treatment of adult patients with unresectable
